Several previous meta-analyses (16–20) confirmed the cardiorenal benefits of SGLT2 inhibitors in T2DM patients, while some other meta-analyses (21–23) confirmed those in HF patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.